Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
Status:
Completed
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
This is a European multinational, multicenter, non-interventional (observational) and
prospective study. It is carried on to confirm in real life conditions the benefit/risk of
vandetanib (CAPRELSA™) 300 mg, both in RET negative and RET positive patients with
symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC.